Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Sanofi-Aventis Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (351)
ARTG (221)
Australian Public Assessment Report (AusPAR) (32)
Prescription medicine registration (32)
Section 14, TGO91 consent (23)
Prescription medicine decision summary (9)
Designation or determination (8)
Prescription medicine evaluation (1)

Date

2024 (29)
2023 (48)
2022 (26)
2021 (102)
2020 (61)
2019 (127)
2018 (41)
2017 (23)
2016 (26)
2015 (14)
2014 (22)
2013 (8)
2012 (3)
2010 (2)
2009 (12)
2008 (6)
2007 (12)
2006 (12)
2005 (15)
2004 (5)
2003 (3)
2002 (7)
2001 (4)
2000 (12)
1999 (5)
1998 (4)
1997 (1)
1996 (10)
1995 (2)
1994 (6)
1993 (6)
1991 (23)

Results for "[search-keyword]"

Search

Sponsor content

677 result(s) found, displaying 421 to 430

DILTIAZEM CD SANOFI diltiazem hydrochloride 180mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

4 May 2018

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
DILTIAZEM CD SANOFI diltiazem hydrochloride 240mg capsule blister pack Cancelled under Section 30(1)(c) of the Act

4 May 2018

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
DILTIAZEM CD SANOFI diltiazem hydrochloride 360mg capsule bottle. Cancelled under Section 30(1)(c) of the Act

4 May 2018

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
SODIUM VALPROATE SANOFI EC200 sodium valproate 200mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

4 May 2018

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
SODIUM VALPROATE SANOFI EC500 sodium valproate 500mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

4 May 2018

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
AMISULPRIDE SANOFI amisulpride 100 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

4 May 2018

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
AMISULPRIDE SANOFI amisulpride 200 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

4 May 2018

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
AMISULPRIDE SANOFI amisulpride 400 mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

4 May 2018

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
FRUSEMIDE SANOFI furosemide (frusemide) 20mg tablet bottle Cancelled under Section 30(1)(c) of the Act

4 May 2018

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd
FRUSEMIDE SANOFI furosemide (frusemide) 40mg tablet bottle Cancelled under Section 30(1)(c) of the Act

4 May 2018

Cancellation by sponsor

Requested by Sanofi-Aventis Australia Pty Ltd

Pages

First page
Previous page
…
Page 39
Page 40
Page 41
Page 42
Current page 43
Page 44
Page 45
Page 46
Page 47
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.